Early versus Later Anticoagulation for Stroke with Atrial Fibrillation.
Urs FischerMasatoshi KogaDaniel StrbianMattia BrancaStefanie AbendSven TrelleMaurizio PaciaroniGötz ThomallaPatrik MichelKrassen NedeltchevLeo H BonatiGeorge NtaiosThomas GattringerElse-Charlotte SandsetPeter KellyRobin LemmensP N SylajaDiana Aguiar de SousaNatan M BornsteinZuzana GdovinovaTakeshi YoshimotoMarjaana TiainenHelen ThomasManju KrishnanGek C ShimChristoph GumbingerJochen VehoffLiqun ZhangKosuke MatsuzonoEspen Saxhaug KristoffersenPhilippe DesfontainesPeter VanackerAngelika AlonsoYusuke YakushijiCaterina KulykDimitri HemelsoetSven PoliAna Paiva NunesNicoletta CaraccioloPeter SladeJelle DemeestereAlexander SalernoMarkus KneihslTimo KahlesDaria GiudiciKanta TanakaSilja RätyRea HidalgoDavid J WerringMartina GöldlinMarcel ArnoldCecilia FerrariSeraina BeyelerChristian FungBruno J WederTurgut TatlisumakSabine FenzlBeata Rezny-KasprzakArsany HakimGeorgia SalantiClaudio BassettiJan GrallaDavid J SeiffgeThomas HorvathJesse Dawsonnull nullPublished in: The New England journal of medicine (2023)
In this trial, the incidence of recurrent ischemic stroke, systemic embolism, major extracranial bleeding, symptomatic intracranial hemorrhage, or vascular death at 30 days was estimated to range from 2.8 percentage points lower to 0.5 percentage points higher (based on the 95% confidence interval) with early than with later use of DOACs. (Funded by the Swiss National Science Foundation and others; ELAN ClinicalTrials.gov number, NCT03148457.).
Keyphrases
- atrial fibrillation
- direct oral anticoagulants
- oral anticoagulants
- catheter ablation
- left atrial
- left atrial appendage
- heart failure
- clinical trial
- public health
- percutaneous coronary intervention
- risk factors
- quality improvement
- study protocol
- venous thromboembolism
- internal carotid artery
- phase ii
- open label
- brain injury
- double blind
- drug induced
- optical coherence tomography